New Drug Development for Known and Emerging Viruses

AvHelga Rübsamen-Schaeff,Helga Rübsamen-Schaeff

Inbunden, Engelska, 2021

Del 80 i serien Methods & Principles in Medicinal Chemistry

2 247 kr

Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt över 249 kr.

Beskrivning

Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decadesWritten by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic.New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. Covers the entire field of antiviral drug discovery and developmentAddresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angleDiscusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issuesNew Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the ;pharmaceutical industry and public health agencies.

Produktinformation

Utgivningsdatum:2021-12-29
Mått:170 x 244 x 30 mm
Vikt:1 134 g
Format:Inbunden
Språk:Engelska
Serie:Methods & Principles in Medicinal Chemistry
Antal sidor:528
Förlag:Wiley-VCH Verlag GmbH
ISBN:9783527343379

Utforska kategorier

Kemi inom Naturvetenskap och teknik
Biologi inom Naturvetenskap och teknik

Mer om författaren

Helga Rübsamen-Schaeff , PhD, is founding CEO of AiCuris and the chair of AiCuris' Scientific Advisory Board. Before founding AiCuris she served at Bayer as SVP and Head of Infectious Disease Research. Before that time, she was Scientific and Managing Director of the Georg-Speyer-Haus in Frankfurt. A chemist by training, Professor Rübsamen-Schaeff has been professor of biochemistry at the University of Frankfurt since 1988. Her research interests focus on research and development of antiviral drugs, novel resistance-breaking antibiotics, emerging infectious diseases and oncology. Prevymis, a drug against HCMV discovered under her direction has reached the market. Helmut Buschmann, PhD, has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors in different therapeutic areas, from pain research to anti-infectives. Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at AiCuris and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.

Innehållsförteckning

Human Immunodeficiency Virus (HIV): Targets for therapy and open issuesHuman Immunodeficiency Virus (HIV): Anti-HIV drug discovery and developmentHepatitis C Virus (HCV): Curing chronic HCV infectionsInfluenza Virus: Targets and drugsRespiratory Syncytial Virus (RSV): Enzymology, antiviral targets, and drugs in developmentHepatitis B Virus (HBV): Development of therapeutic vaccinesHepatitis B Virus (HBV): Drug targetsHepatitis B Virus (HBV): Medicinal chemistry of capsid inhibitorsHepatitis B Virus (HBV): Immunomodulators (Replicor and AIC 649)Human Cytomegalovirus (HCMV): HMCV polymerase as drug targetHuman Cytomegalovirus (HCMV): Inhibitors of HMCV terminaseHerpes Simplex Virus (HSV): Targets and inhibitorsAdeno VirusesdsDNA Viruses: Antiviral strategies for EBV, human polyoma virus and human herpesvirus 6ssDNA Viruses: Antiviral strategies for parvovirus B19Negative-sense ssRNA viruses: Antiviral strategies for Ebola, Marburg, Hendra, Nipah, Lassa, Junin and Machupo virusesPositive-sense ssRNA viruses: Antiviral strategies